Clinical Trial Update: A Multicenter Placebo-Controlled Double-Blind Trial to Evaluate Azidothymidine (AZT) Treatment of the AIDS Dementia Complex and Central Nervous System (CNS) Human Immunodeficiency Virus (HIV) Infection [Phase 3]

View source ↗

Summary

A multicenter Phase 3 double-blind trial evaluating azidothymidine (AZT) for AIDS dementia complex and CNS HIV infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aids Dementia Complex
• HIV Infections

Drugs mentioned

• Azidothymidine (zidovudine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: AIDS Dementia Complex, HIV Infections | Phase 3 | Status: COMPLETED